Richard S. Finn, MD, provides an overview of the systemic treatment options for advanced unresectable hepatocellular carcinoma.
Richard S. Finn, MD: When we talk about systemic treatment for advanced liver cancer, we have had several advances in the last several years. Historically, sorafenib was first approved in 2008, and it was the only systemic treatment for advanced liver cancer until around 2017, when regorafenib was approved in the second-line setting.
We are now going to concentrate on patients with newly diagnosed advanced liver cancer: patients who progressed on TACE [transarterial chemoembolization] or those who present to clinic with advanced disease. We know that sorafenib, as mentioned, was the standard of care until the approval of lenvatinib in the frontline setting. Lenvatinib, like sorafenib, is a VEGF receptor kinase inhibitor. It is multitargeted, and it has a different kinase inhibitory profile than sorafenib.
No. 1, it is potent against the VEGF receptor family, and it also has significant activity against the fibroblast growth factor receptor. These 2 things differentiate it quite a bit from sorafenib, at least scientifically. We saw in the REFLECT study that, when compared to sorafenib in this open-label study, overall survival for lenvatinib, while numerically a little longer, was noninferior by statistical design: it was not superior. It improved progression-free survival significantly, and it had an objective response rate of about 19%.
Based on these data, lenvatinib received approval for frontline therapy, and it has a little different [adverse] effect profile. While both sorafenib and lenvatinib cause GI [gastrointestinal] toxicity, such as diarrhea, anorexia, and weight loss, and both can cause hypertension, but the degree and frequency of hypertension is higher with lenvatinib. The incidence of proteinuria is more frequent and higher grade with lenvatinib vs sorafenib, which is reflecting its potent VEGF receptor activity. However, also differentiating them is the fact that hand-foot-skin reaction syndrome, or HFSR, is more common and more intense with sorafenib.
Transcript edited for clarity.
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More